Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NAPSTER
NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma
- NCT05024318 ↗
- Unknown
- Peter MacCallum Cancer Centre, Australia
- Focused
We haven't built an HCP commentary report on NAPSTER (pembrolizumab in clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NAPSTER so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 8 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma: Investigating Induced Immune Context Changes
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Renal Cell Carcinoma, Clear Cell, Somatic
- Interventions
- Pembrolizumab; Stereotactic Ablative Radiotherapy; Nephrectomy
- Arms
- SABR plus nephrectomy · Active comparator
- Pembrolizumab followed by SABR after cycle 1 plus nephrectomy · Experimental
- Enrollment
- 20 (estimated)
- Primary outcomes
- mPR post-SABR with or without pembrolizumab
- CD8+ TRM in baseline biopsy and post-nephrectomy specimen, all measured as a continuous variable.
- TCF-1 + tumour infiltrating lymphocytes (TILs) in baseline biopsy and post-nephrectomy specimen, measured as a continuous variable
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Start
- Feb 8, 2022
- Primary completion
- Dec 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05024318 · updated May 16, 2024